Skip to main content
Top
Published in: Journal of Medical Ultrasonics 2/2020

01-04-2020 | Ultrasound | Special Feature: Review Article

Application of new ultrasound techniques for focal liver lesions

Authors: Feiqian Wang, Kazushi Numata, Hiromi Nihonmatsu, Masahiro Okada, Shin Maeda

Published in: Journal of Medical Ultrasonics | Issue 2/2020

Login to get access

Abstract

Ultrasonography (US) has the overwhelming advantages of not entailing radiation exposure and being a noninvasive, real-time, convenient, easy-to-perform, and relatively inexpensive imaging modality. It is used as the first-line imaging modality for screening, detection, and diagnosis of focal liver lesions (FLLs) [small hepatocellular carcinomas (HCCs), in particular]. However, with the increasing demand for accurate and early diagnosis of small HCCs, newer radiologic methods need to be explored to overcome certain limitations of US. For example, the imaging is easily negatively affected by the presence of gas, rib cage, and subcutaneous fat, and is insensitive for capturing the subtle but vital information on the blood flow. It was in response to this need that new promising technologies such as contrast-enhanced ultrasound and fusion imaging were introduced for the detection of liver lesions. This paper presents an overview of the epidemiology and mechanisms of the development of HCCs, with an emphasis on the application of US in the diagnosis and treatment of FLLs. The aim of this article is to provide the state-of-the-art developments in the imaging diagnosis of FLLs and evaluation of ablation treatment of early HCCs. By keeping abreast of these recent advances, we hope that doctors and researchers working in the field of diagnosis/treatment of liver diseases will be able to discriminate benign FLLs such as regenerative nodules and focal nodular hyperplasia from HCCs, so as to avoid unnecessary repeated tumor biopsies and overtreatment. In particular, we expect that small HCCs or precancerous nodules (such as dysplastic nodules) can be accurately diagnosed and appropriately treated even at an early stage.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1–17.PubMed Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1–17.PubMed
2.
go back to reference Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–9.PubMed Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–9.PubMed
3.
go back to reference Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140–51.PubMedPubMedCentral Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140–51.PubMedPubMedCentral
4.
go back to reference Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int. 2017;11:317–70.PubMedPubMedCentral Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int. 2017;11:317–70.PubMedPubMedCentral
5.
go back to reference Jiang HY, Chen J, Xia CC, et al. Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis. World J Gastroenterol. 2018;24:2348–62.PubMedPubMedCentral Jiang HY, Chen J, Xia CC, et al. Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis. World J Gastroenterol. 2018;24:2348–62.PubMedPubMedCentral
6.
go back to reference Miller ZA, Lee KS. Screening for hepatocellular carcinoma in high-risk populations. Clin Imaging. 2016;40:311–4.PubMed Miller ZA, Lee KS. Screening for hepatocellular carcinoma in high-risk populations. Clin Imaging. 2016;40:311–4.PubMed
7.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
8.
go back to reference Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43:13–25. Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43:13–25.
9.
go back to reference Cassinotto C, Aube C, Dohan A. Diagnosis of hepatocellular carcinoma: An update on international guidelines. Diagn Interv Imaging. 2017;98:379–91.PubMed Cassinotto C, Aube C, Dohan A. Diagnosis of hepatocellular carcinoma: An update on international guidelines. Diagn Interv Imaging. 2017;98:379–91.PubMed
10.
go back to reference De Cobelli F, Marra P, Ratti F, et al. Microwave ablation of liver malignancies: comparison of effects and early outcomes of percutaneous and intraoperative approaches with different liver conditions: new advances in interventional oncology: state of the art. Med Oncol. 2017;34:49.PubMed De Cobelli F, Marra P, Ratti F, et al. Microwave ablation of liver malignancies: comparison of effects and early outcomes of percutaneous and intraoperative approaches with different liver conditions: new advances in interventional oncology: state of the art. Med Oncol. 2017;34:49.PubMed
11.
go back to reference Santambrogio R, Cigala C, Barabino M, et al. Intraoperative ultrasound for prediction of hepatocellular carcinoma biological behaviour: prospective comparison with pathology. Liver Int. 2018;38:312–20.PubMed Santambrogio R, Cigala C, Barabino M, et al. Intraoperative ultrasound for prediction of hepatocellular carcinoma biological behaviour: prospective comparison with pathology. Liver Int. 2018;38:312–20.PubMed
12.
go back to reference Chung YE, Kim KW. Contrast-enhanced ultrasonography: advance and current status in abdominal imaging. Ultrasonography. 2015;34:3–18.PubMed Chung YE, Kim KW. Contrast-enhanced ultrasonography: advance and current status in abdominal imaging. Ultrasonography. 2015;34:3–18.PubMed
13.
go back to reference Park AY, Seo BK. Up-to-date Doppler techniques for breast tumor vascularity: superb microvascular imaging and contrast-enhanced ultrasound. Ultrasonography. 2018;37:98–106.PubMed Park AY, Seo BK. Up-to-date Doppler techniques for breast tumor vascularity: superb microvascular imaging and contrast-enhanced ultrasound. Ultrasonography. 2018;37:98–106.PubMed
14.
go back to reference Mao Y, Mu J, Zhao J, et al. The value of superb microvascular imaging in differentiating benign renal mass from malignant renal tumor: a retrospective study. Br J Radiol. 2018;91:20170601.PubMedPubMedCentral Mao Y, Mu J, Zhao J, et al. The value of superb microvascular imaging in differentiating benign renal mass from malignant renal tumor: a retrospective study. Br J Radiol. 2018;91:20170601.PubMedPubMedCentral
15.
go back to reference Jiang ZZ, Huang YH, Shen HL, et al. Clinical applications of superb microvascular imaging in the liver, breast, thyroid, skeletal muscle, and carotid plaques. J Ultrasound Med. 2019;38:2811–20PubMed Jiang ZZ, Huang YH, Shen HL, et al. Clinical applications of superb microvascular imaging in the liver, breast, thyroid, skeletal muscle, and carotid plaques. J Ultrasound Med. 2019;38:2811–20PubMed
16.
go back to reference Dubinsky TJ, Revels J, Wang S, et al. Comparison of superb microvascular imaging with color flow and power Doppler imaging of small hepatocellular carcinomas. J Ultrasound Med. 2018;37:2915–24.PubMed Dubinsky TJ, Revels J, Wang S, et al. Comparison of superb microvascular imaging with color flow and power Doppler imaging of small hepatocellular carcinomas. J Ultrasound Med. 2018;37:2915–24.PubMed
17.
go back to reference Bonacchi G, Becciolini M, Seghieri M. Superb microvascular imaging: a potential tool in the detection of FNH. J Ultrasound. 2017;20:179–80.PubMedPubMedCentral Bonacchi G, Becciolini M, Seghieri M. Superb microvascular imaging: a potential tool in the detection of FNH. J Ultrasound. 2017;20:179–80.PubMedPubMedCentral
18.
go back to reference Kim TH, Kim SY, Tang A, et al. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019;25:245–63PubMedPubMedCentral Kim TH, Kim SY, Tang A, et al. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019;25:245–63PubMedPubMedCentral
19.
go back to reference Nevin YUEYK. Screening for hepatocellular carcinoma: summary of current guidelines up to 2018. Hepatoma Res. 2018;46:1–10. Nevin YUEYK. Screening for hepatocellular carcinoma: summary of current guidelines up to 2018. Hepatoma Res. 2018;46:1–10.
20.
go back to reference Ungtrakul T, Mahidol C, Chun-On P, et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol. 2016;22:7806–12.PubMedPubMedCentral Ungtrakul T, Mahidol C, Chun-On P, et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol. 2016;22:7806–12.PubMedPubMedCentral
21.
go back to reference Morgan TA, Maturen KE, Dahiya N, et al. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol (NY). 2018;43:41–55. Morgan TA, Maturen KE, Dahiya N, et al. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol (NY). 2018;43:41–55.
22.
go back to reference Shiha G, Ibrahim A, Helmy A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11:1–30.PubMed Shiha G, Ibrahim A, Helmy A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11:1–30.PubMed
23.
go back to reference Kim MJ, Lim JH, Lee SJ, et al. Correlation between the echogenicity of dysplastic nodules and their histopathologically determined fat content. J Ultrasound Med. 2003;22:327–34.PubMed Kim MJ, Lim JH, Lee SJ, et al. Correlation between the echogenicity of dysplastic nodules and their histopathologically determined fat content. J Ultrasound Med. 2003;22:327–34.PubMed
24.
go back to reference Numata K, Fukuda H, Nihonmatsu H, et al. Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease. Abdom Imaging. 2015;40:2372–83.PubMed Numata K, Fukuda H, Nihonmatsu H, et al. Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease. Abdom Imaging. 2015;40:2372–83.PubMed
25.
go back to reference Choi JY, Lee HC, Yim JH, et al. Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis. J Gastroenterol Hepatol. 2011;26:1004–9.PubMed Choi JY, Lee HC, Yim JH, et al. Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis. J Gastroenterol Hepatol. 2011;26:1004–9.PubMed
26.
go back to reference Party IW. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983–93. Party IW. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983–93.
27.
go back to reference Maruyama H, Yoshikawa M, Yokosuka O. Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol. 2008;14:1710–9.PubMedPubMedCentral Maruyama H, Yoshikawa M, Yokosuka O. Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol. 2008;14:1710–9.PubMedPubMedCentral
29.
go back to reference Murakami T, Tsurusaki M. Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer. 2014;3:85–96.PubMedPubMedCentral Murakami T, Tsurusaki M. Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer. 2014;3:85–96.PubMedPubMedCentral
30.
go back to reference Lee DH, Lee JY, Han JK. Superb microvascular imaging technology for ultrasound examinations: initial experiences for hepatic tumors. Eur J Radiol. 2016;85:2090–5.PubMed Lee DH, Lee JY, Han JK. Superb microvascular imaging technology for ultrasound examinations: initial experiences for hepatic tumors. Eur J Radiol. 2016;85:2090–5.PubMed
31.
go back to reference Oliveira IS, Kilcoyne A, Everett JM, et al. Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdom Radiol (NY). 2017;42:1637–49. Oliveira IS, Kilcoyne A, Everett JM, et al. Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdom Radiol (NY). 2017;42:1637–49.
32.
go back to reference Neumaier CE, Bertolotto M, Perrone R, et al. Staging of hilar cholangiocarcinoma with ultrasound. J Clin Ultrasound. 1995;23:173–8.PubMed Neumaier CE, Bertolotto M, Perrone R, et al. Staging of hilar cholangiocarcinoma with ultrasound. J Clin Ultrasound. 1995;23:173–8.PubMed
33.
go back to reference Sidhu PS, Cantisani V, Dietrich CF, et al. The EFSUMB guidelines and recommendations for the clinical practice of Contrast-Enhanced Ultrasound (CEUS) in non-hepatic applications: update 2017 (short version). Ultraschall Med. 2018;39:154–80.PubMed Sidhu PS, Cantisani V, Dietrich CF, et al. The EFSUMB guidelines and recommendations for the clinical practice of Contrast-Enhanced Ultrasound (CEUS) in non-hepatic applications: update 2017 (short version). Ultraschall Med. 2018;39:154–80.PubMed
34.
go back to reference Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 2006;32:1369–75.PubMed Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 2006;32:1369–75.PubMed
35.
go back to reference Chou Y, Liang J, Wang S, et al. Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions. J Med Ultrasound. 2019;27:81.PubMedPubMedCentral Chou Y, Liang J, Wang S, et al. Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions. J Med Ultrasound. 2019;27:81.PubMedPubMedCentral
36.
go back to reference Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform contrast-enhanced ultrasound (CEUS). Ultrasound Int Open. 2018;4:E2–15.PubMedPubMedCentral Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform contrast-enhanced ultrasound (CEUS). Ultrasound Int Open. 2018;4:E2–15.PubMedPubMedCentral
37.
go back to reference Hatanaka K, Kudo M, Minami Y, et al. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology. 2008;75:42–7.PubMed Hatanaka K, Kudo M, Minami Y, et al. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology. 2008;75:42–7.PubMed
38.
go back to reference Numata K, Fukuda H, Miwa H, et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2014;83:95–102.PubMed Numata K, Fukuda H, Miwa H, et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2014;83:95–102.PubMed
39.
go back to reference Westwood M, Joore M, Grutters J, et al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17:1–243.PubMedPubMedCentral Westwood M, Joore M, Grutters J, et al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17:1–243.PubMedPubMedCentral
40.
go back to reference Tanaka H, Iijima H, Nouso K, et al. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. Hepatol Res. 2012;42:376–84.PubMed Tanaka H, Iijima H, Nouso K, et al. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. Hepatol Res. 2012;42:376–84.PubMed
41.
go back to reference Zhai HY, Liang P, Yu J, et al. Comparison of sonazoid and SonoVue in the diagnosis of focal liver lesions: a preliminary study. J Ultrasound Med. 2019;38:2417–25.PubMed Zhai HY, Liang P, Yu J, et al. Comparison of sonazoid and SonoVue in the diagnosis of focal liver lesions: a preliminary study. J Ultrasound Med. 2019;38:2417–25.PubMed
42.
go back to reference Deng H, Shi H, Lei J, et al. A meta-analysis of contrast-enhanced ultrasound for small hepatocellular carcinoma diagnosis. J Cancer Res Ther. 2016;12:C274–6.PubMed Deng H, Shi H, Lei J, et al. A meta-analysis of contrast-enhanced ultrasound for small hepatocellular carcinoma diagnosis. J Cancer Res Ther. 2016;12:C274–6.PubMed
43.
go back to reference von Herbay A, Vogt C, Willers R, et al. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med. 2004;23:1557–68. von Herbay A, Vogt C, Willers R, et al. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med. 2004;23:1557–68.
44.
go back to reference Xu HX, Lu MD, Liu LN, et al. Discrimination between neoplastic and non-neoplastic lesions in cirrhotic liver using contrast-enhanced ultrasound. Br J Radiol. 2012;85:1376–84.PubMedPubMedCentral Xu HX, Lu MD, Liu LN, et al. Discrimination between neoplastic and non-neoplastic lesions in cirrhotic liver using contrast-enhanced ultrasound. Br J Radiol. 2012;85:1376–84.PubMedPubMedCentral
45.
go back to reference Chen MH, Yang W, Dai Y, et al. High mechanical index post-contrast ultrasonography improves tissue structural display of hepatocellular carcinoma. Chin Med J (Engl). 2005;118:2046–51. Chen MH, Yang W, Dai Y, et al. High mechanical index post-contrast ultrasonography improves tissue structural display of hepatocellular carcinoma. Chin Med J (Engl). 2005;118:2046–51.
46.
go back to reference Yang W, Chen MH, Wu W, et al. Effects of Gray-Scale ultrasonography immediate Post-Contrast on characterization of focal liver lesions. Biomed Res Int. 2015;2015:193178.PubMedPubMedCentral Yang W, Chen MH, Wu W, et al. Effects of Gray-Scale ultrasonography immediate Post-Contrast on characterization of focal liver lesions. Biomed Res Int. 2015;2015:193178.PubMedPubMedCentral
47.
go back to reference Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada T, Izumi N, Sumino Y. B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. Liver Cancer. 2019;4:271–80. Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada T, Izumi N, Sumino Y. B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. Liver Cancer. 2019;4:271–80.
48.
go back to reference Wu M, Li L, Wang J, et al. Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis. Eur Radiol. 2018;28:2077–88.PubMed Wu M, Li L, Wang J, et al. Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis. Eur Radiol. 2018;28:2077–88.PubMed
49.
go back to reference Shi W, He Y, Ding W, et al. Contrast-enhanced ultrasonography used for post-treatment responses evaluation of radiofrequency ablations for hepatocellular carcinoma: a meta-analysis. Br J Radiol. 2016;89:20150973.PubMedPubMedCentral Shi W, He Y, Ding W, et al. Contrast-enhanced ultrasonography used for post-treatment responses evaluation of radiofrequency ablations for hepatocellular carcinoma: a meta-analysis. Br J Radiol. 2016;89:20150973.PubMedPubMedCentral
50.
go back to reference Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver–update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2013;34:11–29.PubMed Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver–update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2013;34:11–29.PubMed
51.
go back to reference Mauri G, Porazzi E, Cova L, et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging. 2014;5:209–16.PubMedPubMedCentral Mauri G, Porazzi E, Cova L, et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging. 2014;5:209–16.PubMedPubMedCentral
52.
go back to reference Nanashima A, Tobinaga S, Abo T, et al. Usefulness of sonazoid-ultrasonography during hepatectomy in patients with liver tumors: a preliminary study. J Surg Oncol. 2011;103:152–7.PubMed Nanashima A, Tobinaga S, Abo T, et al. Usefulness of sonazoid-ultrasonography during hepatectomy in patients with liver tumors: a preliminary study. J Surg Oncol. 2011;103:152–7.PubMed
53.
go back to reference Numata K, Morimoto M, Ogura T, et al. Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med. 2008;27:395–406.PubMed Numata K, Morimoto M, Ogura T, et al. Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med. 2008;27:395–406.PubMed
54.
go back to reference Nihonmatsu H, Numata K, Fukuda H, et al. Low mechanical index contrast mode versus high mechanical index contrast mode: which is a more sensitive method for detecting Sonazoid microbubbles in the liver of normal subjects? J Med Ultrason. 2001;2016:211–7. Nihonmatsu H, Numata K, Fukuda H, et al. Low mechanical index contrast mode versus high mechanical index contrast mode: which is a more sensitive method for detecting Sonazoid microbubbles in the liver of normal subjects? J Med Ultrason. 2001;2016:211–7.
55.
go back to reference Blomley MJ, Albrecht T, Cosgrove DO, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: Early experience. Radiology. 1999;210:409–16.PubMed Blomley MJ, Albrecht T, Cosgrove DO, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: Early experience. Radiology. 1999;210:409–16.PubMed
56.
go back to reference Takizawa K, Numata K, Morimoto M, et al. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol. 2013;82:1471–80.PubMed Takizawa K, Numata K, Morimoto M, et al. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol. 2013;82:1471–80.PubMed
57.
go back to reference Luo W, Numata K, Kondo M, et al. Sonazoid-enhanced ultrasonography for evaluation of the enhancement patterns of focal liver tumors in the late phase by intermittent imaging with a high mechanical index. J Ultrasound Med. 2009;28:439–48.PubMed Luo W, Numata K, Kondo M, et al. Sonazoid-enhanced ultrasonography for evaluation of the enhancement patterns of focal liver tumors in the late phase by intermittent imaging with a high mechanical index. J Ultrasound Med. 2009;28:439–48.PubMed
58.
go back to reference Duisyenbi Z, Numata K, Nihonmatsu H, et al. Comparison between low mechanical index and high mechanical index contrast modes of contrast-enhanced ultrasonography: evaluation of perfusion defects of hypervascular hepatocellular carcinomas during the post-vascular phase. J Ultrasound Med. 2019;38:2329–38.PubMed Duisyenbi Z, Numata K, Nihonmatsu H, et al. Comparison between low mechanical index and high mechanical index contrast modes of contrast-enhanced ultrasonography: evaluation of perfusion defects of hypervascular hepatocellular carcinomas during the post-vascular phase. J Ultrasound Med. 2019;38:2329–38.PubMed
59.
go back to reference Luo W, Numata K, Morimoto M, et al. Clinical utility of contrast-enhanced three-dimensional ultrasound imaging with Sonazoid: findings on hepatocellular carcinoma lesions. Eur J Radiol. 2009;72:425–31.PubMed Luo W, Numata K, Morimoto M, et al. Clinical utility of contrast-enhanced three-dimensional ultrasound imaging with Sonazoid: findings on hepatocellular carcinoma lesions. Eur J Radiol. 2009;72:425–31.PubMed
60.
go back to reference Luo W, Numata K, Morimoto M, et al. Three-dimensional contrast-enhanced sonography of vascular patterns of focal liver tumors: pilot study of visualization methods. AJR Am J Roentgenol. 2009;192:165–73.PubMed Luo W, Numata K, Morimoto M, et al. Three-dimensional contrast-enhanced sonography of vascular patterns of focal liver tumors: pilot study of visualization methods. AJR Am J Roentgenol. 2009;192:165–73.PubMed
61.
go back to reference Luo W, Numata K, Morimoto M, et al. Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. Radiology. 2009;251:287–95.PubMed Luo W, Numata K, Morimoto M, et al. Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. Radiology. 2009;251:287–95.PubMed
62.
go back to reference Luo W, Numata K, Morimoto M, et al. Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies. World J Gastroenterol. 2010;16:2109–19.PubMedPubMedCentral Luo W, Numata K, Morimoto M, et al. Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies. World J Gastroenterol. 2010;16:2109–19.PubMedPubMedCentral
63.
go back to reference Luo W, Numata K, Morimoto M, et al. Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. Eur J Radiol. 2010;75:91–7.PubMed Luo W, Numata K, Morimoto M, et al. Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. Eur J Radiol. 2010;75:91–7.PubMed
64.
go back to reference Numata K, Fukuda H, Ohto M, et al. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocellular carcinoma by three-dimensional sonography with a perflubutane-based contrast agent. Eur J Radiol. 2010;75:e67–75.PubMed Numata K, Fukuda H, Ohto M, et al. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocellular carcinoma by three-dimensional sonography with a perflubutane-based contrast agent. Eur J Radiol. 2010;75:e67–75.PubMed
65.
go back to reference Sugimori K, Numata K, Okada M, et al. Central vascular structures as a characteristic finding of regenerative nodules using hepatobiliary phase gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced MRI and arterial dominant phase contrast-enhanced US. J Med Ultrason. 2001;2017:89–100. Sugimori K, Numata K, Okada M, et al. Central vascular structures as a characteristic finding of regenerative nodules using hepatobiliary phase gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced MRI and arterial dominant phase contrast-enhanced US. J Med Ultrason. 2001;2017:89–100.
66.
go back to reference Nishigori S, Numata K, Irie K, et al. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography. J Med Ultrason. 2001;2018:405–15. Nishigori S, Numata K, Irie K, et al. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography. J Med Ultrason. 2001;2018:405–15.
67.
go back to reference Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology. 2010;78:40–5.PubMed Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology. 2010;78:40–5.PubMed
68.
go back to reference Kozaka K, Kobayashi S, Yoneda N, et al. Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: Imaging and clinicopathological features. Eur Radiol. 2019;29:6489–98PubMed Kozaka K, Kobayashi S, Yoneda N, et al. Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: Imaging and clinicopathological features. Eur Radiol. 2019;29:6489–98PubMed
69.
go back to reference Maruyama H, Takahashi M, Sekimoto T, et al. Heterogeneity of microbubble accumulation: a novel approach to discriminate between well-differentiated hepatocellular carcinomas and regenerative nodules. Ultrasound Med Biol. 2012;38:383–8.PubMed Maruyama H, Takahashi M, Sekimoto T, et al. Heterogeneity of microbubble accumulation: a novel approach to discriminate between well-differentiated hepatocellular carcinomas and regenerative nodules. Ultrasound Med Biol. 2012;38:383–8.PubMed
70.
go back to reference Lim JH, Kim EY, Lee WJ, et al. Regenerative nodules in liver cirrhosis: findings at CT during arterial portography and CT hepatic arteriography with histopathologic correlation. Radiology. 1999;210:451–8.PubMed Lim JH, Kim EY, Lee WJ, et al. Regenerative nodules in liver cirrhosis: findings at CT during arterial portography and CT hepatic arteriography with histopathologic correlation. Radiology. 1999;210:451–8.PubMed
71.
go back to reference Suzuki M, Maeyama S, Takahashi H, et al. Strategy for hepatic hyperplastic nodules in heavy drinkers. Alcohol Clin Exp Res. 2004;28:153S–8S.PubMed Suzuki M, Maeyama S, Takahashi H, et al. Strategy for hepatic hyperplastic nodules in heavy drinkers. Alcohol Clin Exp Res. 2004;28:153S–8S.PubMed
72.
go back to reference Zhang R, Qin S, Zhou Y, et al. Comparison of imaging characteristics between hepatic benign regenerative nodules and hepatocellular carcinomas associated with Budd-Chiari syndrome by contrast enhanced ultrasound. Eur J Radiol. 2012;81:2984–9.PubMed Zhang R, Qin S, Zhou Y, et al. Comparison of imaging characteristics between hepatic benign regenerative nodules and hepatocellular carcinomas associated with Budd-Chiari syndrome by contrast enhanced ultrasound. Eur J Radiol. 2012;81:2984–9.PubMed
73.
go back to reference Lee J, Jeong WK, Lim HK, et al. Focal nodular hyperplasia of the liver: contrast-enhanced ultrasonographic features with sonazoid. J Ultrasound Med. 2018;37:1473–80.PubMed Lee J, Jeong WK, Lim HK, et al. Focal nodular hyperplasia of the liver: contrast-enhanced ultrasonographic features with sonazoid. J Ultrasound Med. 2018;37:1473–80.PubMed
74.
go back to reference Sciarra A, Di Tommaso L, Nakano M, et al. Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. J Hepatol. 2016;64:87–93.PubMed Sciarra A, Di Tommaso L, Nakano M, et al. Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. J Hepatol. 2016;64:87–93.PubMed
75.
go back to reference Guo LH, Xu HX. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: controversy over the ASSLD guideline. Biomed Res Int. 2015;2015:349172.PubMedPubMedCentral Guo LH, Xu HX. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: controversy over the ASSLD guideline. Biomed Res Int. 2015;2015:349172.PubMedPubMedCentral
76.
go back to reference Joshita S, Ichijo T, Suzuki F, et al. A case of well-differentiated cholangiolocellular carcinoma visualized with contrast-enhanced ultrasonography using Sonazoid. Hepatol Res. 2009;39:207–12.PubMed Joshita S, Ichijo T, Suzuki F, et al. A case of well-differentiated cholangiolocellular carcinoma visualized with contrast-enhanced ultrasonography using Sonazoid. Hepatol Res. 2009;39:207–12.PubMed
77.
go back to reference Ishii N, Suzuki H, Tsukagoshi M, et al. Giant cholangiolocellular carcinoma with early recurrence that was difficult to distinguish from cholangiocellular carcinoma: report of a case. Int Surg. 2015;100:1111–6.PubMedPubMedCentral Ishii N, Suzuki H, Tsukagoshi M, et al. Giant cholangiolocellular carcinoma with early recurrence that was difficult to distinguish from cholangiocellular carcinoma: report of a case. Int Surg. 2015;100:1111–6.PubMedPubMedCentral
78.
go back to reference Ishii N, Araki K, Yamanaka T, et al. Small cholangiolocellular carcinoma that was difficult to distinguish from cholangiocellular carcinoma: a case report. Surg Case Rep. 2017;3:103.PubMedPubMedCentral Ishii N, Araki K, Yamanaka T, et al. Small cholangiolocellular carcinoma that was difficult to distinguish from cholangiocellular carcinoma: a case report. Surg Case Rep. 2017;3:103.PubMedPubMedCentral
79.
go back to reference Dietrich CF, Tannapfel A, Jang HJ, et al. Ultrasound imaging of hepatocellular adenoma using the new histology classification. Ultrasound Med Biol. 2019;45:1–10.PubMed Dietrich CF, Tannapfel A, Jang HJ, et al. Ultrasound imaging of hepatocellular adenoma using the new histology classification. Ultrasound Med Biol. 2019;45:1–10.PubMed
80.
go back to reference Yoshioka M, Watanabe G, Uchinami H, et al. Hepatic angiomyolipoma: differential diagnosis from other liver tumors in a special reference to vascular imaging—importance of early drainage vein. Surg Case Rep. 2015;1:11.PubMedPubMedCentral Yoshioka M, Watanabe G, Uchinami H, et al. Hepatic angiomyolipoma: differential diagnosis from other liver tumors in a special reference to vascular imaging—importance of early drainage vein. Surg Case Rep. 2015;1:11.PubMedPubMedCentral
81.
go back to reference Numata K. Advances in ultrasound systems for hepatic lesions in Japan. J Med Ultrason. 2015;42:297–301. Numata K. Advances in ultrasound systems for hepatic lesions in Japan. J Med Ultrason. 2015;42:297–301.
82.
go back to reference Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer. 2014;3:97–107.PubMedPubMedCentral Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer. 2014;3:97–107.PubMedPubMedCentral
83.
go back to reference Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of japan. Liver Cancer. 2014;3:458–68.PubMedPubMedCentral Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of japan. Liver Cancer. 2014;3:458–68.PubMedPubMedCentral
84.
go back to reference Kudo M. Breakthrough imaging in hepatocellular carcinoma. Liver Cancer. 2016;5:47–54.PubMed Kudo M. Breakthrough imaging in hepatocellular carcinoma. Liver Cancer. 2016;5:47–54.PubMed
85.
go back to reference Campos JT, Sirlin CB, Choi JY. Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas. Insights Imaging. 2012;3:451–74.PubMedPubMedCentral Campos JT, Sirlin CB, Choi JY. Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas. Insights Imaging. 2012;3:451–74.PubMedPubMedCentral
86.
go back to reference Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Investig Radiol. 2008;43:504–11. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Investig Radiol. 2008;43:504–11.
87.
go back to reference Liu X, Jiang H, Chen J, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2017;23:1505–18.PubMed Liu X, Jiang H, Chen J, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2017;23:1505–18.PubMed
88.
go back to reference Joo I, Lee JM. Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-Enhanced MRI. Liver Cancer. 2016;5:67–87.PubMed Joo I, Lee JM. Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-Enhanced MRI. Liver Cancer. 2016;5:67–87.PubMed
89.
go back to reference Kudo M. Defect reperfusion imaging with Sonazoid(R): a breakthrough in hepatocellular carcinoma. Liver Cancer. 2016;5:1–07.PubMed Kudo M. Defect reperfusion imaging with Sonazoid(R): a breakthrough in hepatocellular carcinoma. Liver Cancer. 2016;5:1–07.PubMed
90.
go back to reference Jang JY, Kim MY, Jeong SW, et al. Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clin Mol Hepatol. 2013;19:1–16.PubMedPubMedCentral Jang JY, Kim MY, Jeong SW, et al. Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clin Mol Hepatol. 2013;19:1–16.PubMedPubMedCentral
91.
go back to reference Kudo M, Hatanaka K, Kumada T, et al. Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol. 2011;106:368–70.PubMed Kudo M, Hatanaka K, Kumada T, et al. Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol. 2011;106:368–70.PubMed
92.
go back to reference Ntoulia A, Anupindi SA, Darge K, et al. Applications of contrast-enhanced ultrasound in the pediatric abdomen. Abdom Radiol (NY). 2018;43:948–59. Ntoulia A, Anupindi SA, Darge K, et al. Applications of contrast-enhanced ultrasound in the pediatric abdomen. Abdom Radiol (NY). 2018;43:948–59.
93.
go back to reference Ungermann L, Elias P, Zizka J, et al. Focal nodular hyperplasia: spoke-wheel arterial pattern and other signs on dynamic contrast-enhanced ultrasonography. Eur J Radiol. 2007;63:290–4.PubMed Ungermann L, Elias P, Zizka J, et al. Focal nodular hyperplasia: spoke-wheel arterial pattern and other signs on dynamic contrast-enhanced ultrasonography. Eur J Radiol. 2007;63:290–4.PubMed
94.
go back to reference Giorgio A, Calisti G, di Sarno A, et al. Characterization of dysplastic nodules, early hepatocellular carcinoma and progressed hepatocellular carcinoma in cirrhosis with contrast-enhanced ultrasound. Anticancer Res. 2011;31:3977–82.PubMed Giorgio A, Calisti G, di Sarno A, et al. Characterization of dysplastic nodules, early hepatocellular carcinoma and progressed hepatocellular carcinoma in cirrhosis with contrast-enhanced ultrasound. Anticancer Res. 2011;31:3977–82.PubMed
95.
go back to reference Endo K, Kuroda H, Kakisaka K, et al. Hepatic angiomyolipoma staining in the post-vascular phase of contrast-enhanced ultrasound due to the presence of macrophages. Intern Med. 2018;57:1247–51.PubMed Endo K, Kuroda H, Kakisaka K, et al. Hepatic angiomyolipoma staining in the post-vascular phase of contrast-enhanced ultrasound due to the presence of macrophages. Intern Med. 2018;57:1247–51.PubMed
Metadata
Title
Application of new ultrasound techniques for focal liver lesions
Authors
Feiqian Wang
Kazushi Numata
Hiromi Nihonmatsu
Masahiro Okada
Shin Maeda
Publication date
01-04-2020
Publisher
Springer Singapore
Published in
Journal of Medical Ultrasonics / Issue 2/2020
Print ISSN: 1346-4523
Electronic ISSN: 1613-2254
DOI
https://doi.org/10.1007/s10396-019-01001-w

Other articles of this Issue 2/2020

Journal of Medical Ultrasonics 2/2020 Go to the issue